Study summary

Finerenone cut worsening heart failure in people with preserved pumping

FINEARTS-HF trial (finerenone) · 6,001 people, phase 3 · Published September 2024, New England Journal of Medicine

842worsening heart failure events with finerenone, vs 1,024 with placebo

What was tested

Finerenone, a non-steroid mineralocorticoid receptor antagonist pill, against placebo in heart failure with an ejection fraction of 40% or more (mildly reduced or preserved).

What they found

What it means

Gives HFpEF and HFmrEF a second proven drug class after SGLT2 inhibitors.

N Engl J Med, via PubMed ↗ Trial record NCT04435626 ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.